Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same author

NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

Leaflet Modification Technique With UNICORN in Failed Aortic Bioprosthesis: Procedural Step-by-Step, Best Practice, and Troubleshooting.

JACC. Cardiovascular interventions·2026
Same author

BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.

JACC. Cardiovascular interventions·2026
Same author

Chordal-Zone Free Externalization of Retrograde Wire to Facilitate Base-to-Tip LAMPOON.

JACC. Cardiovascular interventions·2026
Same author

Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion.

American journal of clinical pathology·2026

Related Experiment Video

Updated: Jun 21, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Plasma cell myeloma.

Pei Lin1

  • 1Department of Hematopathology, University of Texas-MD Anderson Cancer Center, Houston, TX 77070, USA. peilin@mdanderson.org

Hematology/Oncology Clinics of North America
|July 7, 2009
PubMed
Summary
This summary is machine-generated.

Plasma cell myeloma is a complex cancer with varied outcomes. Advances in therapies are improving patient survival by targeting tumor biology.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Oncology
  • Hematology

Background:

  • Plasma cell myeloma is a heterogeneous malignancy.
  • Clinical presentation and patient outcomes vary significantly.
  • Tumor biology is a key determinant of prognosis.

Purpose of the Study:

  • To review the impact of newer therapeutic agents on myeloma prognosis.
  • To highlight the role of tumor biology in disease progression.

Main Methods:

  • Literature review of recent clinical trials and therapeutic advancements.
  • Analysis of prognostic factors in plasma cell myeloma.

Main Results:

  • Emerging therapeutic agents demonstrate improved survival rates.
  • Understanding tumor biology aids in personalized treatment strategies.

Conclusions:

  • Therapeutic innovations are transforming the outlook for myeloma patients.
  • Targeting specific tumor biology is crucial for enhanced treatment efficacy.